, Volume 67, Issue 5, pp 647–655

Drospirenone for Oral Contraception and Hormone Replacement Therapy

Are its Cardiovascular Risks and Benefits the Same as Other Progestogens?
Current Opinion

DOI: 10.2165/00003495-200767050-00001

Cite this article as:
Motivala, A. & Pitt, B. Drugs (2007) 67: 647. doi:10.2165/00003495-200767050-00001


The use of combined estrogen/progesterone has been shown to result in an increased cardiovascular risk in randomised double-blinded trials. However, these studies used oral progestogen (progestin) preparations, which lack anti-mineralocorticoid activity and have suboptimal anti-androgenic activity compared with progesterone. Drospirenone is a unique progestogen that has clinically been shown to have anti-mineralocorticoid/anti-androgenic effects. Drospirenone in combination with estrogen is currently being used for oral contraception and hormone replacement therapy, and has been shown to have favourable effects on a number of cardiovascular risk factors. Our review of the literature suggests that because of its anti-mineralocorticoid effects, drospirenone in conjunction with estrogen may prevent the development of cardiovascular disease in both pre- and post-menopausal women.

Copyright information

© Adis Data Information BV 2007

Authors and Affiliations

  1. 1.Division of Cardiovascular Medicine, Department of Internal MedicineUniversity of Michigan Health System, University of Michigan Medical CenterAnn ArborUSA

Personalised recommendations